Browse the evidence

Long-term use of GLP-1 receptor agonists (specifically liraglutide, dulaglutide, and exenatide) is associated with an increased risk of thyroid tumors, including C-cell hyperplasia and medullary thyroid carcinoma, primarily through the stimulation of GLP-1 receptors on thyroid C cells leading to calcitonin gene expression and cellular hyperplasia.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Victoza), your doctor should monitor your thyroid health, specifically checking calcitonin levels and potentially performing ultrasounds if you have symptoms or risk factors. This is because these drugs stimulate thyroid C-cells, which can lead to hyperplasia in animal models. While human risk is debated, caution is advised, especially if you have a family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2 (MEN2).

GLP-1 receptor agonists may increase the risk of acute pancreatitis and pancreatic cancer, although meta-analyses have sometimes excluded this risk, and the evidence remains inconclusive with conflicting study results.

Be aware of symptoms of pancreatitis (severe abdominal pain, nausea, vomiting) while on GLP-1 medications. While the absolute risk is debated, it is a known potential side effect. Report any persistent abdominal pain to your doctor immediately.

Chronic inflammation in RA and PsA contributes to increased CVD risk, but the prevalence of Metabolic Syndrome (MetS) alone may not fully account for this risk, particularly in RA where MetS prevalence is similar to the general population.

Having RA or PsA increases your CVD risk beyond just traditional factors like blood pressure or cholesterol. This is partly due to chronic inflammation. Therefore, comprehensive care should address both metabolic risks (like MetS components) and inflammatory control, not just one or the other.

GLP-1 receptor agonists (semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide) are associated with statistically significant signals for otolaryngologic adverse events, specifically GERD, Medullary Thyroid Carcinoma (MTC), and Papillary Thyroid Carcinoma (PTC), across all approved drugs.

If you take a GLP-1 drug like Ozempic or Wegovy, be aware that reports of acid reflux (GERD) and thyroid issues (MTC/PTC) are significantly higher than background noise in the FDA database. You should discuss these risks with your doctor and monitor for symptoms like persistent heartburn or neck lumps, but do not stop medication without medical advice.

Semaglutide and Liraglutide show significant signals for specific otolaryngologic adverse events including anosmia, dysgeusia, Bell's palsy, and tinnitus, which are not as strongly or consistently reported with other GLP-1 RAs.

If you take Semaglutide or Liraglutide and experience loss of smell, taste changes, ringing in the ears, or facial weakness (Bell's palsy), these are reported side effects. Inform your healthcare provider, as these may require management adjustments.

Patients with severe obesity perceive obesity as a disease due to a lack of control and addiction-like mechanisms, yet simultaneously maintain a belief in personal responsibility and self-blame, creating a barrier to accepting the disease label fully.

Understand that accepting obesity as a disease is complex for many patients. While biological factors like genetics and appetite dysregulation play a huge role, many patients still feel personal responsibility. This internal conflict can hinder treatment. Healthcare providers should address this shame and the 'addiction' narrative to help patients accept medical interventions without feeling they are failing morally.

Dietary supplementation with omega-3 polyunsaturated fatty acids (specifically DHA) attenuates nonalcoholic steatohepatitis (NASH) and fibrosis by suppressing betacellulin (BTC) expression, thereby inhibiting hepatic stellate cell proliferation and collagen production.

To support liver health and potentially reduce fibrosis risk, prioritize dietary sources of Docosahexaenoic Acid (DHA), a type of Omega-3 fatty acid. Research suggests DHA is particularly effective at suppressing betacellulin, a protein that drives liver scarring. While general Omega-3s help, DHA appears to have a stronger specific effect on this pathway. Consult a healthcare provider before making significant dietary changes, especially if you have existing liver conditions.

Dual activation of GPR10 and NPFF2 receptors by lipidated PrRP31 metabolites produces robust, long-acting weight loss in diet-induced obese mice, whereas GPR10-selective activation does not.

This research suggests that for obesity treatment, targeting both GPR10 and NPFF2 receptors simultaneously may be more effective than targeting GPR10 alone. The study used lipidated peptides in mice, showing significant weight loss. This is preclinical data and not a direct human treatment recommendation yet.

Obstructive Sleep Apnea (OSA) is an independent risk factor for the development of Type 2 Diabetes (T2DM) and MASLD, primarily through mechanisms of intermittent hypoxia, sympathetic hyperactivity, and inflammation, rather than solely through obesity.

Treating sleep apnea is not just about feeling rested; it is a critical step in preventing diabetes and liver disease. The lack of oxygen during sleep triggers stress hormones and inflammation that damage metabolism.

Continuous Positive Airway Pressure (CPAP) therapy has mixed and often limited effects on improving glycemic control (A1c, fasting glucose) and liver fat content in patients with OSA, T2DM, and MASLD, despite reducing sympathetic activity.

CPAP is essential for treating OSA and improving blood pressure, but it may not significantly lower blood sugar or liver fat on its own. If you have diabetes or fatty liver, focus on weight loss and medications, as CPAP alone may not reverse these conditions.

Excessive protein intake (above recommended levels for amateurs) does not enhance muscle growth or strength outcomes in amateur bodybuilders and may lead to negative health effects such as kidney strain and increased body fat.

Stop overcomplicating your protein intake. If you are an amateur, you do not need extreme amounts of protein. The paper states that high protein does not enhance effects for amateurs and may cause health issues. Focus on a balanced diet with 1.6-1.8 g/kg of protein from whole foods. This is sufficient for muscle growth and avoids the risks of excessive supplementation.

Pioglitazone administration reverses hyperglycemia and restores beta-cell maturity markers (increased insulin/Nkx6.1, decreased Aldh1a3) in diabetic db/db mice, while promoting a 'browning' gene expression profile (UCP-1, Cidea) in white adipose tissue.

Pioglitazone effectively lowers blood glucose and improves beta-cell function in insulin-resistant individuals, even if it causes some weight gain. This gain is largely subcutaneous and correlates with improved metabolic health. It also promotes 'browning' markers in fat tissue, suggesting enhanced metabolic flexibility.

Chronic administration of the dual beta-2/beta-3 adrenergic agonist ATR-127 significantly reduces body weight and fat mass while improving glucose homeostasis in diet-induced obese mice, without causing cardiac hypertrophy.

This research suggests that a specific drug targeting fat and muscle metabolism (ATR-127) can reduce body fat and improve blood sugar control in obese individuals without harming the heart, a common side effect of older weight-loss drugs. This is currently only proven in mice and lab cells, so it is not yet available for human use.

Post-exercise cold water immersion (CWI) attenuates resistance training-induced muscle hypertrophy compared to resistance training alone.

If your main goal is building maximum muscle size, avoid cold water immersion immediately after your resistance training sessions. The evidence suggests that cooling the muscles right after lifting blunts the biological signals (like protein synthesis and mTOR signaling) required for growth. If you must use CWI for recovery, schedule it at least several hours away from your training or on rest days to minimize interference with hypertrophy.

Intensive lifestyle intervention (ILI) involving weight loss and increased physical activity does not reduce the rate of major cardiovascular events in adults with type 2 diabetes and a history of cardiovascular disease, and may be associated with a higher incidence of nonfatal myocardial infarction compared to diabetes support and education.

If you have type 2 diabetes and a history of heart disease, intensive lifestyle changes focusing on heavy weight loss and high-volume exercise may not protect your heart and could potentially increase the risk of a non-fatal heart attack compared to standard education. Consult your doctor before starting intense exercise programs to ensure they are safe for your specific cardiac condition.

Targeting specific protein posttranslational modifications (PTMs) such as phosphorylation, ubiquitination, and acetylation offers therapeutic potential for metabolic diseases including diabetes, obesity, and NAFLD by modulating insulin signaling, glucose metabolism, and inflammatory pathways.

This paper suggests that future treatments for metabolic diseases may target specific molecular switches (PTMs) in your cells. While you cannot directly 'dose' these switches, understanding them explains why current drugs (like SGLT-2 inhibitors or GLP-1 agonists) are effective and why lifestyle changes (diet/exercise) that influence these pathways (e.g., AMPK activation) are beneficial. Consult a doctor about emerging therapies targeting these pathways.

Use of GLP-1 receptor agonists (semaglutide and tirzepatide) is associated with an increased risk of alopecia, potentially mediated by rapid weight loss-induced telogen effluvium or direct receptor interaction in hair follicles.

If you are taking semaglutide or tirzepatide and notice increased hair shedding, do not panic. This is likely telogen effluvium caused by rapid weight loss or metabolic stress, which is usually reversible. Ensure you are eating enough protein and nutrients. Talk to your doctor; they may adjust your plan or provide reassurance, but stopping the medication abruptly is rarely necessary unless the shedding is severe.

Quercetin and Resveratrol supplementation do not improve physical performance or recovery markers in military personnel.

Do not rely on Quercetin or Resveratrol for performance or recovery benefits. They do not improve aerobic capacity or physical performance in military personnel.

The presence of satellite cells reduces ex vivo skeletal muscle force production specifically during the morning, whereas this effect is absent in the afternoon.

If you are training for maximum force output, be aware that your muscles may naturally produce less force in the morning due to circadian regulation. This is not a sign of weakness, but a biological rhythm. If possible, schedule heavy strength training in the afternoon when this circadian suppression is absent.

The reduced force production in the morning associated with satellite cells results in significantly less contractile injury (force loss and dystrophin-negative fibers) following eccentric exercise.

Eccentric exercise causes damage, but the extent of damage varies by time of day. Morning training with satellite cells present may result in less structural damage (dystrophin loss) than afternoon training, potentially due to lower force generation. This suggests morning might be a safer time for high-intensity eccentric work if injury prevention is the goal.

The reduced force production in the morning is mechanistically linked to lower calcium availability for contractile units, as indicated by reduced caffeine-induced contracture force.

This is a basic science finding. It suggests that the reason morning muscles might be weaker is not just neural, but involves how much calcium is available to trigger contraction. This is not directly actionable for training but informs future research on timing.

GLP-1 receptor agonists do not exacerbate psychotic symptoms in schizophrenia and provide metabolic benefits, but have not demonstrated consistent effects on core psychiatric symptomatology.

For people with schizophrenia, GLP-1 medications are safe and help with weight gain caused by antipsychotics, but they do not treat the psychosis itself. Do not expect them to improve hallucinations or cognitive function. They are a tool for metabolic health, not psychiatric symptom management in this population.

Tirzepatide significantly reduces urine albumin-to-creatinine ratio (UACR) compared to placebo and insulin, indicating improved renal microvascular health, while maintaining a neutral effect on estimated glomerular filtration rate (eGFR) over short-term follow-up.

If you have Type 2 Diabetes or obesity, Tirzepatide (5-15 mg weekly) significantly lowers albuminuria (a marker of kidney stress) compared to placebo or insulin, without negatively impacting your kidney's filtration rate over 6-18 months. This suggests renal protection, particularly for those with existing high albuminuria. However, long-term data is still needed.

Combining GIPR agonism or antagonism with GLP-1 R agonism produces synergistic weight loss in preclinical models, whereas GIPR signaling is not required for this synergy in humans.

Combining GIP and GLP-1 hormones (as seen in drugs like tirzepatide) is more effective for weight loss than GLP-1 alone, likely because they work together synergistically. However, the exact way this works in humans is still debated, as animal studies do not perfectly predict human biology.